Omeprazole capsules 10mg №28

Pharmachologic effect.

H inhibitor⁺-K⁺-ATP-ase. Inhibits the activity of H⁺-K⁺-ATP-ase in the parietal cells of the stomach and thereby blocks the final stage of the secretion of hydrochloric acid. This leads to a decrease in basal and stimulated secretion, regardless of the nature of the stimulus. As a consequence of a decrease in acid secretion, the drug reduces or normalizes the effect of acid on the esophagus in patients with reflux esophagitis.
Omeprazole has a bactericidal effect on Helicobacter pylori. Eradication of H. pylori with simultaneous use of Omeprazole and antibiotics allows you to quickly arrest the symptoms of the disease, achieve a high degree of healing of the damaged mucous and persistent long-term remission and reduce the likelihood of bleeding from the gastrointestinal tract.

Pharmacokinetics.

When ingestion is rapidly absorbed from the gastrointestinal tract. It penetrates into the parietal cells of the gastric mucosa. Plasma protein binding is about 95%, predominantly with albumin. Biotransforming in the liver. Excreted by the kidneys - 72-80%, with feces - about 20%. The half-life is 0.5-1 hours. In patients with chronic liver diseases, the half-life increases to 3 hours.

Indications.

Peptic ulcer and duodenal ulcer in the acute phase (includingassociated with Helicobacter pylori), reflux esophagitis, Zollinger-Ellison syndrome, erosive and ulcerative lesions of the stomach and duodenum associated with taking NSAIDs.

Dosing regimen.

Individual. For ingestion a single dose is 20-40 mg. Daily dose - 20-80 mg; frequency of use - 1-2 times / day. The duration of treatment is 2-8 weeks.

Side effect.

Gastrointestinal: rarely - nausea, diarrhea, constipation, abdominal pain, flatulence, dyspeptic disorders.
From the side of the central nervous system: rarely - headache, dizziness, weakness.
Hemic and lymphatic: in some cases - anemia, eosinopenia, neutropenia, thrombocytopenia.
Urogenital: in some cases - hematuria, proteinuria.
Musculoskeletal system: in some cases - arthralgia, muscle weakness, myalgia.
Allergic reactions: rarely a skin rash.

Contraindications.

Chronic liver disease (including a history), hypersensitivity to omeprazole.

Pregnancy and lactation.

Due to the lack of clinical experience, omeprazole is not recommended for use during pregnancy. If necessary, use during lactation should decide on the termination of breastfeeding.

Special instructions.

Before starting therapy, it is necessary to exclude the possibility of the presence of a malignant process (especially in case of a stomach ulcer), since Omeprazole treatment may mask the symptoms and delay the proper diagnosis.
Against the background of the use of omeprazole may be a distortion of the results of laboratory studies of liver function and indicators of the concentration of gastrin in the blood plasma.
Due to the lack of experience with clinical use of omeprazole is not recommended for use in children.
Omeprazole in capsule form is included in the VED list.

Drug interaction.

While taking omeprazole may decrease the absorption of Ketoconazole.
Omeprazole slows excretion of diazepam, Warfarin, phenytoin, as well as other drugs that are metabolized in the liver with the participation of cytochrome P₄₅₀ 2C19.
With long-term simultaneous use of omeprazole and Clarithromycin, their plasma concentrations increase.
With simultaneous use of omeprazole with antacids drug interaction is not marked.

Terms and conditions of storage.
In a dry, dark place, at a temperature not higher than 25'C.
The drug should be kept out of the reach of children.